PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Veena Charu Selected Research
Anemia
10/2007
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
06/2007
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
07/2006
Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
12/2005
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
01/2004
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
07/2003
Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
10/2002
Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
Articles by Research Topic
Disease
7
Anemia
10/2007 - 10/2002
5
Neoplasms (Cancer)
12/2007 - 07/2003
2
Nausea
09/2006 - 12/2003
2
Vomiting
09/2006 - 12/2003
1
Breast Neoplasms (Breast Cancer)
12/2005
1
Fatigue
07/2003
Drug/Important Bio-Agent (IBA)
7
darbepoetin alfa (Aranesp)
FDA Link
10/2007 - 10/2002
4
Epoetin Alfa (Epogen)
FDA Link
07/2006 - 01/2004
2
palonosetron (Aloxi)
FDA Link
09/2006 - 12/2003
1
pegfilgrastim (Neulasta)
FDA Link
12/2007
1
Dexamethasone (Maxidex)
FDA Link
Generic
09/2006
1
aprepitant (Emend)
FDA Link
09/2006
1
5-HT3 Serotonin Receptors (5 HT3 Receptor)
IBA
12/2003
1
dolasetron mesylate (dolasetron)
FDA Link
12/2003
Therapy/Procedure
10
Drug Therapy (Chemotherapy)
12/2007 - 10/2002